Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Cytokine release syndrome (CRS) is a serious and potentially life-threatening complication typically associated with biological drug products. Animal models have been long established to facilitate the study of pathogenesis of the major toxicities of different therapies. However, the mouse models and in vitro human PBMC assays presently in use do not reliably predict CRS in patients. Creative Biolabs offers different kind of in vivo CRS model tools to support your CRS management.
Humanized mouse models provide a potential translational bridge for the study and prediction of CRS in vivo. Studies have suggested the potential of using immunodeficient mice engrafted with human immune systems to study CRS. PBMC engrafted humanized immunodeficient mice are frequently used to study cytokine release in response to several immunotherapeutic, including anti-CD3, anti-CD28, anti-thymocyte globulin (ATG). 
Currently, the only widely accepted predictors of CRS are cancer burden and therapeutic dose. Despite this, most pre-clinical assays that evaluate CRS do not incorporate cancer cells and the safety of drug combinations has not been widely explored. A predictive assay that identifies cancer-patient-therapy combinations at risk for developing CRS upfront would improve the safety of immune-oncology drug development. Scientists at Creative Biolabs have developed different in vivo models to evaluate donor-dependent cytokine release in response to single-agent or combination immune-oncology therapies.
A massive cytokine release can be experimentally induced in serval ways. Lipopolysaccharide (LPS) is a toxin that is routinely used to activate a systemic inflammatory response. LPS-induced cytokine release models have fast kinetics and model the acute phase of the cytokine storm.
Our catalogue or customized in vivo CRS models recapitulates key clinical and pathological features of CRS, forming an integrated platform for preclinical drug development. Creative Biolabs also offers in vitro CRS models. Please feel free to contact us to discuss your next study.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
